Published in Law and Health Weekly, April 15th, 2006
Thomas Lang, Samaritan's chief drug development officer, said enrollment has been completed for the first monotherapy trial.
The trial is a multicenter, double-blind, randomized, placebo-controlled, study of orally administered SP01A as monotherapy, in HIV-infected patients. This trial is designed to accrue treatment-experienced HIV patients that are failing on their current anti-viral therapy.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly